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Background:  Ticagrelor reduced mortality by 51% in patients who underwent coronary artery bypass grafting (CABG) in the PLATO study, 
but its effect on graft patency is unknown.
methods:  We performed a prospective, randomized, blinded, placebo-controlled trial, comparing ticagrelor 90mg bid versus placebo for 3 
months added to aspirin 81mg/d, following isolated CABG. Informed consent was obtained prior to CABG, and those who survived surgery 
with no contraindication post-CABG to aspirin or ticagrelor were randomized. Aspirin was started within 12 hours, and study medication 
within 48-72 hours after CABG. The primary outcome was bypass graft anastomotic occlusion on CT angiography performed 3 months 
post-CABG. Patients were followed to 12 months for death, MI, stroke, repeat revascularization, and bleeding. The study was designed 
with 80% power to detect a reduction of graft occlusion rate from 15% to 10%, with 2-sided p-value 0.05. Assuming an average of 2.5 
grafts/patient and 10% rate of non-analyzable grafts, the estimated sample size was 240 patients.
results:  The study was terminated prematurely after the randomization of 70 patients between September 2011 and August 2014 
because of slow enrolment. A total of 126 out of 336 screen eligible patients agreed to participate in the trial. Of these, 56 were excluded 
after CABG because of contraindications or withdrawal of consent. Baseline characteristics were similar in the 2 study groups. Completion 
of 3-month study medication was achieved in 25/35 of the ticagrelor group, and 31/35 of the placebo group. Of the 206 graft anastomoses, 
the primary outcome of graft occlusion occurred in 21/88 (23.9%) with ticagrelor and 57/118 (48.3%) with placebo, p<0.0001. Major 
bleeding was 0% in both groups, but minor bleeding was much higher with ticagrelor (31.4% vs. 2.9%, p=0.003), but only 3 (8.6%) required 
early drug discontinuation.
Conclusion:  Ticagrelor added to aspirin after CABG significantly improved graft patency at 3 months, with no increase in major bleeding 
but with significant increases in minor bleeding. Bypass graft occlusion after CABG was much higher than anticipated.
